Summit Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -44 | -4 | ||
EBITDA | -215,700 | -189,380 | -219,080 | |
EBIT | -189,424 | -219,122 | ||
Net Income | -215,700 | -189,424 | -219,172 | -231,793 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -168,747 | -92,926 | -75,776 | -93,151 |
Cash | 419,365 | 80,776 | 167,183 | 238,554 |
Basic Shares | 778,184 | 775,458 | 766,400 | 744,442 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $583 |
Gross Profit | -108 | -15,007 | -2,050 | 583 |
EBITDA | -1,079,390 | -168,455 | -69,451 | -51,583 |
EBIT | -1,079,536 | -168,526 | -69,606 | -52,628 |
Net Income | -1,079,586 | -176,773 | -482,367 | -65,170 |
Net Change In Cash | 0 | 0 | 0 | 583 |
Free Cash Flow | -240,153 | -113,666 | -60,845 | -34,406 |
Cash | 167,183 | 83,794 | 56,522 | 284,182 |
Basic Shares | 747,700 | 718,541 | 619,646 | 193,336 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.28 |
2026-03-31 | -$0.17 |
2025-12-31 | -$0.21 |
2025-09-30 | -$0.23 |